Halozyme Therapeutics | HALO - Trade Creditors


Halozyme Therapeutics reported $14.1M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 12.25M 1.34M Mar/2026
Agios Pharmaceuticals USD 13.75M 4.61M Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amarin USD 48.15M 2.8M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
Baxter International USD 1.09B 87M Mar/2026
Cara Therapeutics USD 3.22M 859K Dec/2025
Cytokinetics USD 24.71M 80.91M Mar/2026
DBV Technologies USD 39.82M 972K Sep/2025
Eli Lilly USD 5.03B 350M Mar/2026
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
MannKind USD 16.14M 7.11M Mar/2026
Minerva Neurosciences USD 640K 305K Dec/2025
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Pfizer USD 4.51B 734M Mar/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
United Therapeutics USD 498.3M 491.2M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024